G. Rosti
About
G. Rosti is a scholar working on Hematology, Genetics and Rheumatology.
According to data from OpenAlex, G. Rosti has authored 24 papers receiving a total of 555 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Hematology, 17 papers in Genetics and 9 papers in Rheumatology. Recurrent topics in G. Rosti's work include Chronic Myeloid Leukemia Treatments (18 papers), Chronic Lymphocytic Leukemia Research (16 papers) and Eosinophilic Disorders and Syndromes (9 papers). G. Rosti is often cited by papers focused on Chronic Myeloid Leukemia Treatments (18 papers), Chronic Lymphocytic Leukemia Research (16 papers) and Eosinophilic Disorders and Syndromes (9 papers). G. Rosti collaborates with scholars based in Italy, United States and Germany. G. Rosti's co-authors include Giuseppe Saglio, Giovanni Martinelli, Francesca Palandri, Fausto Castagnetti, Nicoletta Testoni, Simona Soverini, Ilaria Iacobucci, Simona Luatti, Daniela Cilloni and M. Marangolo and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.
In The Last Decade
G. Rosti
24 papers receiving 540 citations
Peers
G. Rosti
Ekkehard Eigendorff Germany
Chandrika N. Nair India
Jeiry Filian United States
Armin Leitner Germany
Fabrizio Ciccone Italy
TL Smith United States
Elisabeth Wehrle Switzerland
AS Stein United States
J Score United Kingdom
Jerry Radich United States
Citations per year, relative to G. Rosti G. Rosti (= 1×)
peers
Ekkehard Eigendorff
Countries citing papers authored by G. Rosti
Since
Specialization
Citations
This map shows the geographic impact of G. Rosti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Rosti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Rosti more than expected).
Fields of papers citing papers by G. Rosti
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by G. Rosti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Rosti. The network helps show where G. Rosti may publish in the future.
Co-authorship network of co-authors of G. Rosti
This figure shows the co-authorship network connecting the top 25 collaborators of G. Rosti. A scholar is included among the top collaborators of G. Rosti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. Rosti. G. Rosti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Rossi, Andrea, Massimo Breccia, Elisabetta Abruzzese, et al.. (2012). Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors. Haematologica. 98(3). 399–403.
2.
Breccia, Massimo, Roberto Latagliata, Fabio Stagno, et al.. (2011). Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib. Haematologica. 96(10). 1457–1461.
3.
Rosti, G., Fausto Castagnetti, Francesca Palandri, et al.. (2010). Efficacy and safety of nilotinib 800 mg daily in early chronic phase Ph+ chronic myeloid leukemia: Results of a phase II trial at 2 years.. Journal of Clinical Oncology. 28(15_suppl). 6515–6515.
4.
Soverini, Simona, Sabrina Angelini, Mark Thornquist, et al.. (2010). Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia (CML) patients.. Journal of Clinical Oncology. 28(15_suppl). 6554–6554.
5.
Palandri, Francesca, Fabio Castagnetti, Simona Soverini, et al.. (2009). Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure. Haematologica. 94(12). 1758–1761.
6.
Coutre, Philipp le, Francis J. Giles, Jane F. Apperley, et al.. (2008). Nilotinib in accelerated phase chronic myelogenous leukemia (CML-AP) patients with imatinib-resistance or -intolerance: Update of a phase II study. Journal of Clinical Oncology. 26(15_suppl). 7050–7050.
7.
Bandini, Giuseppe, Elisa Zuffa, G. Rosti, et al.. (2008). Long-term outcome of adults with acute myelogenous leukaemia: results of a prospective, randomized study of chemotherapy with a minimal follow-up of 7 years. British Journal of Haematology. 77(4). 486–490.
8.
Palandri, Francesca, Ilaria Iacobucci, Fausto Castagnetti, et al.. (2008). Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon- : 5-year outcome. Haematologica. 93(5). 770–774.
9.
Rosti, G., Fausto Castagnetti, Francesca Palandri, et al.. (2008). Nilotinib 800 mg daily as first line treatment of chronic myeloid leukemia in early chronic phase: results of a phase II trial of the GIMEMA CML Working Party. Journal of Clinical Oncology. 26(15_suppl). 7054–7054.
10.
Jabbour, Elias, Andreas Hochhaus, Philipp le Coutre, et al.. (2008). Minimal cross-intolerance between nilotinib and imatinib in patients with imatinib-intolerant chronic myelogenous leukemia (CML) in chronic phase (CP) or accelerated phase (AP). Journal of Clinical Oncology. 26(15_suppl). 7063–7063.
11.
Soverini, Simona, Sabrina Colarossi, Alessandra Gnani, et al.. (2007). Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica. 92(3). 401–404.
12.
Rosti, G., Ilaria Iacobucci, Fausto Castagnetti, et al.. (2007). Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party. Haematologica. 92(1). 101–105.
13.
Rosti, G., Philipp le Coutre, Kapil N. Bhalla, et al.. (2007). A phase II study of nilotinib administered to imatinib resistant and intolerant patients with chronic myelogenous leukemia (CML) in chronic phase (CP). Journal of Clinical Oncology. 25(18_suppl). 7007–7007.
14.
Giles, Francis J., Philipp le Coutre, Kapil N. Bhalla, et al.. (2007). A phase II study of nilotinib administered to patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who also failed dasatinib. Journal of Clinical Oncology. 25(18_suppl). 7038–7038.
15.
Talpaz, Moshe, P Rousselot, François Guilhot, et al.. (2005). A Phase II Study of Dasatinib in Patients with Chronic Myeloid Leukemia (CML) in Myeloid Blast Crisis Who Are Resistant or Intolerant to Imatinib: First Results of the CA180006 ‘START-B’ Study.. Blood. 106(11). 40–40.
16.
Dazzi, Claudio, Anna Cariello, Petros Giovanis, et al.. (2003). Prophylaxis with GM-CSF mouthwashes does not reduce frequency and duration of severe oral mucositis in patients with solid tumors undergoing high-dose chemotherapy with autologous peripheral blood stem cell transplantation rescue: a double blind, randomized, placebo-controlled study. Annals of Oncology. 14(4). 559–563.
17.
Dazzi, Claudio, Anna Cariello, Massimo Carlo Giannini, et al.. (2000). A sequential chemo-radiotherapeutic treatment for patients with malignant gliomas: a phase II pilot study.. PubMed. 20(1B). 515–8.
18.
Rosti, G., et al.. (1991). High dose chemotherapy with carboplatin, VP 16 +/- ifosfamide in germ cell tumors: the Italian experience.. PubMed. 7 Suppl 2. 94–94.
19.
Zaccaria, Alfonso, Nicoletta Testoni, Feyruz V. Rassool, et al.. (1989). Cytogenetic and molecular studies in patients with chronic myeloid leukemia and variant Philadelphia translocations. Cancer Genetics and Cytogenetics. 42(2). 191–201.
20.
Ravaioli, Alessandra, Marina Faedi, G. Rosti, et al.. (1986). Primary gastric lymphoma: A review of 45 cases. European Journal of Cancer and Clinical Oncology. 22(12). 1461–1465.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Ekkehard Eigendorff Breakdown of academic impact, for papers by Chandrika N. Nair Breakdown of academic impact, for papers by Jeiry Filian Breakdown of academic impact, for papers by Armin Leitner Breakdown of academic impact, for papers by Fabrizio Ciccone Breakdown of academic impact, for papers by TL Smith Breakdown of academic impact, for papers by Elisabeth Wehrle Breakdown of academic impact, for papers by AS Stein Breakdown of academic impact, for papers by J Score Breakdown of academic impact, for papers by Jerry Radich